plumbagin

11/01/2014 - "However, the therapeutic efficacy of plumbagin is overshadowed by the lack of sensitivity and selectivity towards cancer cells. "
02/01/2015 - "The in vivo anti-tumor efficacy of plumbagin was demonstrated using a mouse model. "
12/01/2023 - "In vitro cancer studies showed that plumbagin triggers apoptosis in cancer cells through ROS production. "
12/01/2022 - "The present study revealed that alteration in miR-22-3p levels by plumbagin contributes to the induction of apoptosis and its inhibitory effects on Wnt signaling and colony formation, thus providing a mechanistic basis behind its anti-cancer potential."
09/01/2022 - "Our previous study reported that plumbagin exhibits potent anti-cancer actions. "

05/31/2023 - "In this review, the most relevant mechanisms in which Plumbagin plays a role in the process of inflammation were summarized. "
05/31/2023 - "Among this class of compounds, Plumbagin, a plant-derived product, has shown interesting counteracting effects in many inflammation models. "
01/01/2018 - "In addition, plumbagin protected inflammation-induced bone loss by inhibiting osteoclast formation and activity. "
12/13/2016 - "Additionally, plumbagin hampered inflammation related NF-κB signal in RAW 264.7 cells. "
04/01/2016 - "These effects suggest that treatment with BMSCs combined with plumbagin alleviates SCI through its effects on oxidative stress, inflammation, apoptotis and activation of the Nrf2 pathway."

09/05/2022 - "This study provides mechanistic insight into the anticancer activity of plumbagin in breast cancer cells under hypoxic conditions by abolishing HIF-1α at transcription and post-translational modifications."
01/01/2020 - "Our previous study reported the inhibitory effect of Plumbagin (PLB) on human endocrine resistant breast cancer cell growth and cell invasion. "
01/01/2019 - "The aim of this study was to investigate the anticancer effects of plumbagin isolated from Nepenthes alata against MCF-7 breast cancer cells. "
09/01/2015 - "The aim of this study was to investigate the effects of ZA combined with a natural anticancer compound plumbagin (PL) against human breast cancer cells in vitro. "
12/01/2006 - "This study is the first to investigate the anticancer effect of plumbagin in human breast cancer cells. "

12/01/2017 - "This study evaluates the effectiveness of treatment with combinations of plumbagin and alternative strategies for ADT in mouse models of prostate cancer to support its clinical use. "
03/01/2016 - "In this study, we have analyzed the effect of Plumbagin (PB) and structurally related naphthaquinones on BRCA1/2 silenced prostate cancer cells and the ability of PB to target stem cells. "
09/01/2008 - "The present study points towards an important role of ROS in plumbagin-induced apoptosis in human prostate cancer cells."
01/01/2022 - "Induction of Apoptosis and Autophagy via sirtuin1- and PI3K/Akt/mTOR-Mediated Pathways by Plumbagin in Human Prostate Cancer Cells [Retraction]."
01/01/2022 - "Novel Capryol 90-based nanoemulsion formulation of plumbagin demonstrated antiproliferative activity against prostate cancer cells, warranting thus further pharmaceutical development."

06/01/2016 - "For better understanding of the antimicrobial activity of plumbagin, a Drosophila melanogaster infection model was used, where D. "
01/01/2020 - "Plumbagin may be used in combination with aminoglycosides for severe CRKp infection by potentiating their therapeutic efficacy and lowering dosage."
06/01/2022 - "Natural component plumbagin as a potential antibacterial agent against Streptococcus agalactiae infection."
01/01/2019 - "In neonatal mouse models of CT- and rotavirus infection-induced diarrhea, 0.4 µg plumbagin inhibited secretory diarrhea by >40% and 50%, respectively, without affecting intestinal epithelial integrity or the rotaviral infection. "
01/01/2022 - "In conclusion, the combination of plumbagin and colistin shows a prominently synergistic antibacterial effect in vitro and in vivo, providing a promising option for the therapy of COL-R PA infection."